Library · Oncology, infection & imaging · Multiple myeloma treatment
Belantamab mafodotin
Belantamab mafodotin-blmf, Blenrep
Antibody-drug conjugate targeting BCMA, first FDA-approved in 2020, withdrawn in 2023, then re-approved in October 2025 with bortezomib and dexamethasone for relapsed/refractory multiple myeloma. Delivers a cytotoxic payload directly to myeloma cells.
Research score 82/100. Reference only, not a dose.
Boxed warning: Risk of ocular toxicity including corneal epithelium changes. REMS program required
- Anti-Cancer
- Cytotoxic
- US status
- Prescription Only
- Approval
- FDA Approved (2020, withdrew 2023, re-approved 2025 for combination therapy)
- Evidence
- Combination therapy with bortezomib and dexamethasone showed improved outcomes (2025 approval)
- Research score
- 82 / 100
- Indication
- Relapsed or refractory multiple myeloma
- Origin
- United States
- Source category
- Cancer & Oncology
- Status group
- Approved / prescription
Mechanism
An afucosylated IgG1 antibody binds BCMA on myeloma cells and, once internalized and cleaved, releases the microtubule inhibitor MMAF, arresting the cell cycle and driving apoptosis.
Safety file
Carries a boxed warning for eye toxicity, including corneal changes and vision loss; available only through a restricted REMS program.
- Ocular toxicity (corneal changes, vision changes)
- Infusion reactions